LivaNova (NASDAQ:LIVN) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of LivaNova (NASDAQ:LIVN) in a report released on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $64.00 target price on the stock.

A number of other brokerages also recently issued reports on LIVN. Barclays lifted their price target on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Wolfe Research upgraded shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a report on Tuesday, May 20th. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Robert W. Baird lifted their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $59.71.

LivaNova Stock Down 0.3%

Shares of LIVN stock opened at $57.97 on Wednesday. The company has a market capitalization of $3.17 billion, a price-to-earnings ratio of -14.90 and a beta of 0.97. LivaNova has a one year low of $32.48 and a one year high of $58.42. The company’s fifty day moving average price is $48.67 and its 200-day moving average price is $43.68. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. LivaNova’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.93 EPS. Sell-side analysts expect that LivaNova will post 2.85 EPS for the current fiscal year.

Institutional Trading of LivaNova

A number of large investors have recently made changes to their positions in LIVN. Hsbc Holdings PLC increased its holdings in shares of LivaNova by 25.5% in the 4th quarter. Hsbc Holdings PLC now owns 5,876 shares of the company’s stock worth $272,000 after buying an additional 1,193 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of LivaNova by 11.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,180 shares of the company’s stock worth $1,722,000 after purchasing an additional 3,839 shares during the period. Northern Trust Corp boosted its stake in shares of LivaNova by 11.2% during the 4th quarter. Northern Trust Corp now owns 703,019 shares of the company’s stock worth $32,557,000 after purchasing an additional 70,630 shares during the period. Jane Street Group LLC boosted its stake in shares of LivaNova by 45.5% during the 4th quarter. Jane Street Group LLC now owns 193,826 shares of the company’s stock worth $8,976,000 after purchasing an additional 60,613 shares during the period. Finally, AXA S.A. purchased a new position in shares of LivaNova during the 4th quarter worth about $1,662,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.